Cabozantinib usage, dosage, indications and precautions

Cabozantinib (Cabozantinib) is an oral small molecule tyrosine kinase inhibitor mainly used to treat advanced cancer, especially tumors that are resistant to some targeted therapies. By targeting the inhibitory effects of multiple receptor kinases, the drug can effectively inhibit the proliferation, metastasis and angiogenesis of tumor cells, thus having significant clinical effects on a variety of cancers. The usage, dosage, indications and precautions of cabozantinib will be analyzed in detail below.

1. Indications

Cabozantinib is approved to treat a variety of advanced cancers, particularly in patients who are refractory to conventional therapies. Its indications mainly include:

Renal cell carcinoma (RCC): Cabozantinib is indicated for the treatment of advanced or metastatic renal cell carcinoma, particularly in patients who have received anti-angiogenic therapy.

Hepatocellular carcinoma (HCC): Cabozantinib is also effective in patients with hepatocellular carcinoma who have been previously treated with sorafenib.

Thyroid cancer: Cabozantinib is approved to treat advanced dedifferentiated thyroid cancer.

Neuroendocrine tumors: Cabozantinib has also shown some efficacy, especially when other treatments have failed.

Cabotinib exerts anti-tumor effects by inhibiting the kinase activity of multiple receptors such as VEGFR, MET, and AXL. Its mechanism of action is not limited to anti-tumor proliferation, but can also effectively inhibit tumor metastasis and angiogenesis.

2. Usage and Dosage

Cabozantinib is generally taken as an oral tablet, and the recommended dose is adjusted based on the patient's specific condition, tumor type, and response to treatment. Usual dosage is usually:

Renal cell carcinoma: Initial dose is 60 mg once daily, preferably after a meal. Doses may be titrated based on patient tolerance and efficacy.

Hepatocellular carcinoma: The initial dose is60mg once a day, and the dose is adjusted according to the patient's weight, drug tolerance, etc.

Thyroid cancer: The recommended dose is60mg once a day, and the course of treatment is determined based on the patient's response and tolerance.

Neuroendocrine tumors: The dose can be adjusted based on the patient's weight and tolerance. The usual starting dose is60 mg once daily.

It should be noted that cabozantinib should be taken according to the specific instructions of the doctor, and the dosage should be adjusted based on the patient's specific response. If patients experience obvious adverse reactions while taking the medication, they may need to reduce the dose or suspend the use of the medication.

3. Notes

Although cabozantinib has significant efficacy in the treatment of many tumors, the following points need to be noted during use:

Monitoring of liver and kidney function: Since cabozantinib may have an impact on liver and kidney function, patients need to regularly monitor liver and kidney function while taking the drug. Especially when symptoms of discomfort occur, the drug dose should be adjusted in a timely manner.

High blood pressure: Cabozantinib may cause high blood pressure. Patients need to check their blood pressure regularly during treatment. If the blood pressure is too high, measures should be taken to control it.

Gastrointestinal adverse reactions: Adverse reactions such as nausea, vomiting, and diarrhea are relatively common. Patients should use anti-nausea drugs or adjust the drug dosage under the guidance of a doctor.

Bleeding risk: Cabozantinib may cause thrombocytopenia and increase the risk of bleeding. Patients should seek medical attention in time if abnormal bleeding symptoms occur.

Heart problems: Cabozantinib may have negative effects on the heart, especially in patients with a history of cardiovascular disease, and should be used with caution under the guidance of a physician.

In addition, the safety of cabozantinib in pregnant and nursing women has not been fully established; therefore, patients who are pregnant or planning to become pregnant should avoid using this drug.

Cabozantinib is an effective targeted drug that is widely used to treat a variety of advanced tumors, including renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, and neuroendocrine tumors. It exerts anti-tumor effects by inhibiting tumor angiogenesis, cell proliferation and metastasis. When using it, patients should strictly follow the doctor's instructions and conduct regular inspections and monitoring. Although cabozantinib has a significant therapeutic effect, patients still need to pay attention to its potential adverse reactions, especially in aspects such as liver and kidney function, blood pressure, and digestive tract. Overall, cabozantinib, as an effective targeted therapy, can significantly improve patients' quality of life and survival under appropriate indications.

Reference:https://en.wikipedia.org/wiki/Cabozantinib